The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets).
Denise A. Yardley
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose
Erika Paige Hamilton
No relevant relationships to disclose
Lowell L. Hart
No relevant relationships to disclose
Mythili Shastry
No relevant relationships to disclose
Laura M. DeBusk
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose